• Thurs news: Novartis not joining weight loss race. Pharma marketing and climate change. Roche flu treatment trial. Cercle’s fund raise for women’s health. ICER looks at GSK COPD drugs. See more on our front page

Roche races to regulators after matching AstraZeneca's rare disease blockbuster in phase 3

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Feb 07, 2023 at 11:12: AM
via Roche is ready to wade into the increasingly ferocious fight for the paroxysmal nocturnal hemoglobinuria (PNH) space. The Big Pharma’s subcutaneous contender matched AstraZeneca’s intravenous blockbuster incumbent Soliris in phase 3, positioning it to file for regulatory approvals around the world.

article source
 

<



Similar threads

cafead
Roche reports positive data from Phase III influenza treatment trial
Replies
0
Views
3
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Obesity pill race heats up as Novo, Roche and Terns share data
Replies
0
Views
43
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Roche doubles down with another subcutaneous FDA nod, this one for MS star Ocrevus
Replies
0
Views
32
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
FDA approves Roche’s Tecentriq Hybreza for cancer
Replies
0
Views
19
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
‘The trajectory is encouraging.’ Roche hopes obesity drug will show 25% weight loss one day
Replies
1
Views
64
Pharma/Biotech Companies - In the News
anonymous
Top Bottom
Back
Quote